{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:07:40Z","timestamp":1791209260146,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Else Kr\u00f6ner School for Medical Scientists","award":["2022_EKMK.17"],"award-info":[{"award-number":["2022_EKMK.17"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 9793\/1-1"],"award-info":[{"award-number":["HA 9793\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) improved survival outcomes for patients with metastatic melanoma. Yet up to 65% of patients experience primary resistance and nearly half of initial responders acquire resistance. The clinical utility of ICB is further tempered by frequent immune-related adverse events (irAEs), which increase in severity and frequency with prolonged treatment duration. Hence, a pivotal challenge is to identify clinically accessible markers to predict durable ICB responses. While prior reports indicate that the development of cutaneous irAEs may reflect robust antitumor immune responses, there is limited evidence linking specific types of cutaneous irAEs to clinical ICB benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective multicenter study, we investigated a cohort of 741 patients diagnosed with non-resectable stage III\/IV melanoma who were treated with ICB between April 2012 and August 2025. Patient demographics, tumor characteristics, treatment regimens and survival outcomes were collected within six German skin cancer centers. We stratified patients by the type of cutaneous AE into such with whitening of the body skin (vitiligo), hair (poliosis) or other cutaneous AE. Primary endpoints included progression-free survival (PFS) and objective response rates (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 741 eligible patients, 221 developed cutaneous irAE within the median follow-up period of 48 months. Thereof, we observed tumor recurrences in 17.2% of patients with poliosis, 57.7% of patients developing vitiligo and 60.0% of patients with other cutaneous irAE. In line, we detected a significantly enhanced ORR (93.1% vs 58.8%\u2009vs 38.8%, p\n                      <jats:italic>&lt;<\/jats:italic>\n                      0.001), prolonged PFS (Not reached, NR, vs 31 months vs 9 months, p\n                      <jats:italic>&lt;<\/jats:italic>\n                      0.001) and overall survival (NR vs NR vs 69 months, p&lt;0.001) in poliosis patients. Critically, enhanced tumor control in poliosis patients was seen regardless of initial tumor burden, treatment duration or the presence of melanoma brain metastases. While other AE usually arise early on ICB start, poliosis was a late event that occurred at a median of 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identifies poliosis as a distinct and immunologically-informed marker linked to strong and durable ICB responses easily applicable in a routine clinical setting. Detection of poliosis may complement radiographic imaging for clinical decision-making on ICB treatment duration and early cessation and provides a window for translational investigations harnessing epitope-specific T-cell responses to melanoma antigens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015306","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:34Z","timestamp":1791207334000},"page":"e015306","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study"],"prefix":"10.1136","volume":"14","author":[{"given":"Annika","family":"Brekner","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Mengoni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universitatsklinikum Schleswig-Holstein Campus Lubeck, L\u00fcbeck, Germany"},{"name":"Department of Dermatology, Universit\u00e4tsklinikum Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Mareen","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Lepper","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"Division of Dermal Oncoimmunology, Helmholtz-Institute for Translational Oncology (HI-TRON), Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Veeser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Dietzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Laubach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital T\u00fcbingen, Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henner","family":"Stege","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-7570","authenticated-orcid":false,"given":"Maximilian","family":"Haist","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100506352197000_14.10.e015306.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2026100506352197000_14.10.e015306.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026100506352197000_14.10.e015306.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267"},{"key":"2026100506352197000_14.10.e015306.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2026100506352197000_14.10.e015306.5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"2026100506352197000_14.10.e015306.6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"2026100506352197000_14.10.e015306.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"2026100506352197000_14.10.e015306.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"2026100506352197000_14.10.e015306.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"2026100506352197000_14.10.e015306.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2026100506352197000_14.10.e015306.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172806","article-title":"Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma","volume":"17","author":"K\u00f6tt","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026100506352197000_14.10.e015306.12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2026100506352197000_14.10.e015306.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"2026100506352197000_14.10.e015306.14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026100506352197000_14.10.e015306.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2026.01.001"},{"key":"2026100506352197000_14.10.e015306.16","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.302"},{"key":"2026100506352197000_14.10.e015306.17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/immuno2020020","article-title":"Poliosis is associated with response to checkpoint-inhibitor therapy: a case report of two patients with multifocal metastatic melanoma","volume":"2","author":"Haist","year":"2022","journal-title":"Immuno"},{"key":"2026100506352197000_14.10.e015306.18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.15354","article-title":"A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma","volume":"178","author":"Wolner","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026100506352197000_14.10.e015306.19","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/IOP.0000000000001451","article-title":"Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma","volume":"35","author":"Ediriwickrema","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2026100506352197000_14.10.e015306.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007630","article-title":"Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG","volume":"11","author":"Haist","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026100506352197000_14.10.e015306.21","doi-asserted-by":"crossref","unstructured":"Haist M , Matusiak M , Tan Y , et al . Spatially organized inflammatory myeloid-CD8 + T cell aggregates linked to Merkel-cell Polyomavirus driven Reorganization of the Tumor Microenvironment. bioRxiv 2025.:2025.06.06.657162. doi:10.1101\/2025.06.06.657162","DOI":"10.1101\/2025.06.06.657162"},{"key":"2026100506352197000_14.10.e015306.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026100506352197000_14.10.e015306.23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front Oncol"},{"key":"2026100506352197000_14.10.e015306.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2819-x"},{"key":"2026100506352197000_14.10.e015306.25","first-page":"239","article-title":"Vitiligo and cutaneous melanoma. A case study","volume":"183","author":"Schallreuter","year":"1991","journal-title":"Dermatologica"},{"key":"2026100506352197000_14.10.e015306.26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026100506352197000_14.10.e015306.27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.34004","article-title":"Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"2026100506352197000_14.10.e015306.28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and Vitiligo: In Good Company","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026100506352197000_14.10.e015306.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.005"},{"key":"2026100506352197000_14.10.e015306.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.012"},{"key":"2026100506352197000_14.10.e015306.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1172-6"},{"key":"2026100506352197000_14.10.e015306.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy","volume":"14","author":"Carbone","year":"2023","journal-title":"Front Immunol"},{"key":"2026100506352197000_14.10.e015306.33","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17638","article-title":"Image Gallery: Unilateral eyebrow depigmentation","volume":"180","author":"Amini Adle","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026100506352197000_14.10.e015306.34","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.14683","article-title":"Vasculitis and IgA monoclonal gammopathy of cutaneous significance","volume":"32","author":"Rousset","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100506352197000_14.10.e015306.35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03464.x"},{"key":"2026100506352197000_14.10.e015306.36","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1397067","article-title":"Immune niches for hair follicle development and homeostasis","volume":"15","author":"Kiselev","year":"2024","journal-title":"Front Physiol"},{"key":"2026100506352197000_14.10.e015306.37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00803.x"},{"key":"2026100506352197000_14.10.e015306.38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/exd.14221","article-title":"Immune privilege of skin stem cells: What do we know and what can we learn?","volume":"30","author":"Agudo","year":"2021","journal-title":"Exp Dermatol"},{"key":"2026100506352197000_14.10.e015306.39","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1720","article-title":"Melanocyte stem cells in the skin: Origin, biological characteristics, homeostatic maintenance and therapeutic potential","volume":"14","author":"Huang","year":"2024","journal-title":"Clin Transl Med"},{"key":"2026100506352197000_14.10.e015306.40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/labinvest.2017.8","article-title":"Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance","volume":"97","author":"Aung","year":"2017","journal-title":"Lab Invest"},{"key":"2026100506352197000_14.10.e015306.41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident memory T cells in the skin mediate durable immunity to melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci Immunol"},{"key":"2026100506352197000_14.10.e015306.42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1099108","article-title":"Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data","volume":"12","author":"Rao","year":"2022","journal-title":"Front Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:38Z","timestamp":1791207338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-015306"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015306","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}